Participated · Series B · Jul 2026

Crystalys is advancing dotinurad, a next-generation, once-daily oral URAT1 inhibitor positioned as a second-line therapy to reduce uric acid, gout flares and tophi. Dotinurad was invented by Fuji Yakuhin and has regulatory approvals in Japan, China, the Philippines, Taiwan and Thailand, with supporting clinical data from those markets. The company is conducting the JEWEL clinical research program, which includes the Phase 3 RUBY and TOPAZ trials and the Phase 2 AMETHYST study to evaluate safety and efficacy across a broad spectrum of gout patients. Crystalys aims to position dotinurad as a best-in-class option for safety and efficacy and is preparing for global commercialization. The company is headquartered in San Diego and was co-founded by Catalys Pacific and Novo Holdings. With the announced $130 million Series B, Crystalys has increased its financial runway to support late-stage development and commercial readiness.

Participated · Series B · Aug 2024

Pathalys Pharma is a late-stage clinical biopharmaceutical company based in Research Triangle Park, NC, focused on therapies for end-stage kidney disease (ESKD). Its initial asset is upacicalcet, a novel calcimimetic intended to improve treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients. The company is running two ongoing clinical trials of upacicalcet and intends to use new financing to finalize those studies. Pathalys plans to execute an NDA filing with the U.S. Food and Drug Administration and accelerate preapproval commercialization preparations. Beyond upacicalcet, the company continues to identify additional needs and potential therapeutic solutions for patients with ESKD. The recent financing is intended to support late-stage development, regulatory submission, and commercialization readiness. Pathalys Pharma is a private, late-stage clinical biopharmaceutical company focused on developing advanced therapeutics for end-stage kidney disease (ESKD). Its lead asset is upacicalcet, a novel calcimimetic aimed at improving treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients. The company is led by CEO Neal Fowler and continues to identify other high-priority needs and potential solutions for patients with ESKD. Pathalys has entered a collaboration with Launch Therapeutics to advance the phase 3 clinical trials for upacicalcet; Launch Therapeutics is backed by funds managed by Carlyle and Abingworth. The recently announced financing will support two phase 3 trials, regulatory registration efforts, and pre-commercialization activities for upacicalcet. Pathalys remains a privately held, late-stage clinical-stage biopharma working toward commercialization of its initial asset.

Led · Series A · Jul 2024

Renalys Pharma is a Tokyo-based late-stage clinical biopharmaceutical company focused on developing innovative therapeutics for renal disease in Japanese and Asian patients. The company holds rights to sparsentan via a licensing agreement with Travere Therapeutics. Renalys aims to address “drug loss” by catalyzing access to new treatments for kidney disease across the region. It submitted an IND for sparsentan to Japan’s PMDA in April 2024 and plans to initiate an open-label registrational Phase III study in Q2 2024. The Phase III program targets IgA nephropathy, a prevalent kidney disease in Japan and Asia, with anticipated urine protein/creatinine ratio endpoint results in the second half of 2025. Renalys is led by CEO BT Slingsby and is privately held.

Participated · Seed · Sep 2023

Arialys Therapeutics is developing precision medicines that specifically block pathogenic autoantibodies in the brain to expand treatment options for neuropsychiatric disorders driven by autoimmunity. Its lead program, ART5803, is a therapeutic antibody designed to treat anti‑NMDA receptor encephalitis (ANRE) by blocking NMDAR autoantibodies. The company has generated preclinical proof‑of‑concept data in a nonhuman primate disease model showing ART5803 reverses encephalitis and reduces behavioral symptoms caused by NMDAR autoantibody pathogenicity. ART5803 has received orphan drug designation from the U.S. Food and Drug Administration, and Arialys purchased the asset from Astellas Pharma. The team plans to file an IND next year and advance ART5803 into the clinic for ANRE and autoimmune psychosis. Arialys recently closed $58 million in seed financing to advance its CNS‑targeted precision‑medicine programs and is headquartered in the Avalon BioVentures Accelerator on the Torrey Pines Mesa in La Jolla, California.

Participated · Series B · Jun 2022

Mineralys Therapeutics operates in the biotechnology sector, concentrating on the development of therapeutic innovations. The company recently drew attention amid a broader surge in biotech valuations. According to the article, Mineralys secured $9.5 million in new capital from Findell Capital Management, giving it additional liquidity to advance its research initiatives. While the report does not outline specific drug candidates or clinical programs, the fresh funding underscores investor confidence in the firm’s scientific direction. The financing also signals the company’s intent to accelerate upcoming milestones and strengthen its operational footing. No revenue figures, user metrics, or detailed pipeline information were disclosed in the article.